<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5167133 Figure_1-A</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 1-A</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Western blot analysis of Tace using lysates from WT and TaceFl/Fl;P0-Cre mousesciatic nerves at P10 (65ug of total protein lysate loaded). The arrowhead indicates the pro-protein and the arrow shows the cleaved active form of Tace. Representative of two independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_1-B</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Western blot analysis (50ug of total protein lysate loaded) shows that Tace expression in axons is maximal at P5-P10 and then progressively declines in the adult. Representative of two independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_1-C</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Western blot analysis of Tace in Mtmr2-/- sciatic nerves at P5, P10, and P20. Representative of two independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_1-D</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 1-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Western blot analysis of Tace using lysates from Mtmr2-/- mouse sciatic nerves at 5 months, with quantification, p=0.10, two-tailed Mann Whitney U test. Representative of two independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_1-E</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 1-E</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. Phosphorylation of ErbB2 in Mtmr2-/- sciatic nerves at P2, P10 and P15. At P2, each lane is a pool of n=7 animals per genotype, representative of six independent experiments using n=6 different nerve pools per genotype, and quantification using WT values arbitrary set to1, p=0.0313, Wilcoxon Rank Sum test. At P10 and P15, mean values of two samples are shown. At P10, each lane is a pool of n=3/4 animals per genotype, representative of three independent experiments using n=6 different pools per genotype. Nf-l is the neurofilament light chain and Clx is calnexin.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_1-F</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 1-F</infon>
    <infon key="sourcedata_figure_dir">Figure_1-F</infon>
    <passage>
      <offset>0</offset>
      <text>F. Phosphorylation of ErbB2 in Mtmr2-/- Schwann cell/DRG neuron co-cultures after 4 days of ascorbic acid treatment. Each lane is a pool from at least 10 coverslips/DRG per genotype. Representative of two independent experiments using n=4 different pools of coverslips/DRG per genotype, p=0.20, two-tailed Mann Whitney U test.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_2-A</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 2-A</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. ShRNA targeting Nrg1 type III were validated in rat purified neurons. Western blot analysis for Nrg1 shows reduction of its expression (pro-protein at 150 KDa) using two different harpins, representative of two independent experiments. Clx is calnexin.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_2-B</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 2-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. ShRNA#1 and 2 downregulate Nrg1 type III expression also in myelin-forming Schwann cell/DRG neuron co-cultures analyzed after 7 days of ascorbic acid treatment, as shown by western blot analysis, representative of two independent experiments. Clx is calnexin.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_2-C-D</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 2-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_2-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>C, D. Titration of shRNA #1 (C) and of shRNA #2 (D) LVs (lentiviral vectors) on WT Schwann cell/DRG neuron co-cultures analyzed after 7 days of ascorbic acid treatment, with quantification of the mean number of Mbp positive segments and Schwann cell number. In (C) n= 20 (SCR, Scramble), n= 11 (LV #sh1, 12.5%), n= 16 (LV #sh1, 25%), n= 9 (LV #sh1, 50%) DRG/coverslips from two independent experiments. Results are mean &#177; SEM, p&lt;0.0001, nonparametric one-way ANOVA, followed by Dunn's post hoc test. In (D) n= 14 (SCR), n= 10 (LV #sh2, 12.5%), n= 12 (LV #sh2, 25%), n= 79 (LV #sh2, 50%) DRG/ coverslips, representative of two independent experiments. Results are mean &#177; SEM, p&lt;0.0001, nonparametric one-way ANOVA, followed by Dunn's post hoc test.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_2-E-1</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 2-E-1</infon>
    <infon key="sourcedata_figure_dir">Figure_2-E-1</infon>
    <passage>
      <offset>0</offset>
      <text>E. Representative confocal images of Mtmr2-/- co-cultures transduced using LV expressing Nrg1 type III shRNA #1, with quantification of the percentage of myelin outfoldings, n= number of DRG/coverslips, n= 9, 382 fibers (SCR), n=9, 368 fibers (LV #sh1, 12.5%), n= 8, 327 fibers (LV #sh1, 25%). Asterisks indicate fibers with myelin outfoldings. Results are mean &#177; SEM, p&lt;0.0001, nonparametric one-way ANOVA, followed by Dunn's post hoc test, representative of two independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_2-E-2</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 2-E-2</infon>
    <infon key="sourcedata_figure_dir">Figure_2-E-2</infon>
    <passage>
      <offset>0</offset>
      <text>E. Western blot analysis of Nrg1 and Akt phosphorylation (S473) shows that activation of Akt decreases following Nrg1 type III downregulation (p-Akt/Akt/Actin, ratio between Mtmr2-/- Scramble-treated and Mtmr2-/- sh#1-treated using 12.5% LV is 1 : 0.85). Each lane is a pool of at least 10 different DRG/coverslips, representative of two independent experiments. Bar in (C, D) is 100 &#956;m; in (E) is 20 &#956;m.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_3-A</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 3-A</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Titration of rhTACE on wild-type (WT) co-cultures stained for Mbp with quantification of Mbp positive fibers and Schwann cell nuclei: n=18 (NT, not treated), n=6 (5ng/ml), n=20 (10ng/ml), n=7 (50ng/ml) DRGs/covers from two independent experiments, p=0.0053, nonparametric one-way ANOVA, followed by Dunn's post hoc test.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_3-B-1</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 3-B-1</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B-1</infon>
    <passage>
      <offset>0</offset>
      <text>B. Immunohistochemistry and confocal microscopy of Mtmr2-/- cultures treated with 5ng/ml and 10ng/ml rhTACE, with quantification of the percentage of myelin outfoldings; n=10 (NT), n=10 (5ng/ml), n=11 (10ng/ml), DRGs/coverslips. A total of 547, 557, and 571 Mbp fibers were quantified, respectively, p&lt;0.0001, nonparametric one-way ANOVA, followed by Dunn's post hoc test.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_3-B-2</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 3-B-2</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B-2</infon>
    <passage>
      <offset>0</offset>
      <text>B. Western blot analysis of lysates from Mtmr2-/- cultures treated using 10ng/ml rhTACE showing Nrg1 expression and Akt activation (S473 phosphorylation). Each lane is a lysate of at least n=10 DRGs/coverslips. In Mtmr2-/- (10ng/ml rhTACE) as compared to Mtmr2-/- (NT), Nrg1(150 KDa)/actin ratio is 0.8:1; Nrg1(65 KDa)/actin ratio is 0.48:1; and p-Akt/Akt/actin ratio is 0.6:1.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_3-C</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 3-C</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Titration of WT co-cultures using different amounts of Niacin, nicotinic acid, with quantification of Mbp positive fibers and Schwann cell nuclei, n=9 (NT), n=8 (1mM), n=9 (5mM), n=8 (10mM), DRGs/ coverslips. Representative of three independent experiments, p=0.0055, nonparametric one-way ANOVA, followed by Dunn's post hoc test.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_3-D-3</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 3-D-3</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D-3</infon>
    <passage>
      <offset>0</offset>
      <text>D. Immunohistochemistry and confocal microscopy of Mtmr2-/- cultures treated with 1 mM and 5mM Niacin, with quantification of the percentage of myelin outfoldings; n=31 (NT), n=14 (1mM), and n=29 (5mM) DRGs/coverslips from two independent experiments. A total of 1256, 489, and 1305 fibers, respectively, were quantified, p&lt;0.0001, nonparametric one-way ANOVA, followed by Dunn's post hoc test.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_3-D-4</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 3-D-4</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D-4</infon>
    <passage>
      <offset>0</offset>
      <text>D. Tace activity was measured from lysates of Niacin-treated cultures, n=7 (KO NT) and n=8 (KO 5mM Niacin) number of independent plates, each containing from 10-15 DRGs plated. Note that Tace activity was similar between WT and Mtmr2-/- cultures, one-tailed Mann Whitney U test, p=0.037.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_3-E</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 3-E</infon>
    <infon key="sourcedata_figure_dir">Figure_3-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. Niacin treatment of Tace-/- explants does not rescue hypermyelination, with quantification, n=8 DRGs/coverslips per condition, p=0.0056, nonparametric one-way ANOVA, followed by Dunn's post hoc test. Representative of three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_4-A-B</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 4-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>A. Representative images of semithin section analysis of sciatic nerves from Mtmr2-/- and Mtmr2-/-;Nrg1 (III)+/- mice at 6 months. Myelin outfoldings (arrowheads) are reduced in Mtmr2-/-;Nrg1 (III)+/- nerves (n=9) as compared to Mtmr2-/- (n=8), results are mean &#177; SEM, p=0.0037, two-tailed Mann Whitney U test. B. G-ratio analysis on sciatic nerves from Mtmr2-/-, Mtmr2-/-;Nrg1 (III)+/-, and Nrg1 (III)+/- mice at 6 months indicates that myelin thickness of Mtmr2-/-;Nrg1 (III)+/- is similar to Nrg1 (III)+/- nerves and different from Mtmr2-/-, which is in the normal range as already reported (Bonneick et al, 2005), n=5 animals per genotype. Mean g-ratios: Mtmr2-/- 0.67 &#177; 0.03, 2129 fibers, n=5 animals; Mtmr2-/-;Nrg1 (III)+/- 0.71 &#177; 0.03, 2139 fibers, n=5 animals; Nrg1 (III)+/- 0.72 &#177; 0.03, 2152 fibers, n=4 animals. Mtmr2-/- as compared to Mtmr2-/-;Nrg1 (III)+/-, p=0.0145; Mtmr2-/- as compared to Nrg1 (III)+/-, p=0.0030, and Mtmr2-/-;Nrg1 (III)+/- as compared to Nrg1 (III)+/- p=0.3193, repeated measures ANOVA.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_4-C</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 4-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Western blot analysis on lysates from Mtmr2-/-, Mtmr2-/-;Nrg1 (III)+/-, and Nrg1 (III)+/- sciatic nerves at P10 indicates that Akt activation (S473 phosphorylation) is similar between Mtmr2-/-;Nrg1 (III)+/- and Nrg1 (III)+/- consistent with g-ratio findings, representative of three independent experiments. Phosphorylation of Akt is relative to total Akt normalized on calnexin, Clx.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_5-A-1</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 5-A-1</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A-1</infon>
    <passage>
      <offset>0</offset>
      <text>A. Niacin treatment of Vim-/- explants rescues hypermyelination, n=10 DRGs/ coverslips per condition, with quantification, representative of three independent experiments, p=0.0048, nonparametric one-way ANOVA, followed by Dunn's post hoc test.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_5-A-2</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 5-A-2</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A-2</infon>
    <passage>
      <offset>0</offset>
      <text>A. Western blot analysis on lysates from treated and not treated explants (at least 10 DRGs/ coverslips per lane) shows that increased Akt activation (S473 phosphorylation) in Vim-/- explants is restored to normal levels following 5 mM Niacin treatment.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_5-B-3</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 5-B-3</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B-3</infon>
    <passage>
      <offset>0</offset>
      <text>B. Niaspan treatment of Vim-/- mice does not affect mouse growth, as the growth rate in WT (n=8, saline; n=6 Niaspan) and Vim-/- (n=10 saline and n=10 Niaspan) mice either saline or Niaspan-treated is not significantly different, Linear Mixed Effect (LME) models.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_5-B-4</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 5-B-4</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B-4</infon>
    <passage>
      <offset>0</offset>
      <text>B. Niaspan administration (daily i.p. injection of 160mg/Kg Niaspan starting at P15 for 15 days) enhances Tace activity in Vim-/- nerves at P30, n=6 animals per genotype, p=0.0325, one-tailed Mann Whitney U test.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_5-C</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 5-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Semithin section and g-ratio analyses of sciatic nerves at P30 shows that Niaspan does not alter myelin thickness in WT nerves, whereas restores myelin thickness to normal values in Vim-/- nerves. G-ratio values: WT saline, 0.71 &#177; 0.003, 1872 fibers, n= 5 animals; WT Niaspan, 0.71 &#177; 0.004, 1882 fibers, n= 5 animals; Vim-/- saline 0.69 &#177; 0.004, 2313 fibers, n= 6 animals; Vim-/- Niaspan 0.72 &#177; 0.01, 1616 fibers, n=5 animals. WT saline as compared to Vim-/- saline, p=0.0588; Vim-/- saline as compared to Vim-/- Niaspan, p=0.0431, repeated measures ANOVA, representative of two independent experiments. The number of myelinated fibers is similar between the 4 groups as shown, p=0.3042, nonparametric one-way ANOVA, followed by Dunn's post hoc test.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_6-A</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 6-A</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Niaspan administration (daily i.p. injection of 160mg/Kg starting at P15 for 60 days) does not affect the growth of Mtmr2-/- mice. The growth rates of Mtmr2-/- and WT both saline-treated are significantly different, p&lt;0.0001, Linear Mixed Effect (LME) models, as already reported (Bolino et al, 2004), n=8 animals per condition.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_6-B</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 6-B</infon>
    <infon key="sourcedata_figure_dir">Figure_6-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Niaspan administration reduces the percentage of myelin outfoldings (red asterisks) in Mtmr2-/- sciatic nerves without affecting the number of myelinated fibers as assessed by semithin section analysis at P75, n= 8 mice per genotype, results are mean &#177; SEM, p=0.0093, two-tailed Mann Whitney U test, representative of three independent experiments. Niaspan treatment does not alter myelin thickness in WT or Mtmr2-/- mice as assessed by g-ratio analysis (WT saline-treated, 0.67 &#177; 0.003, 2014 fibers; Mtmr2-/- Niaspan-treated, 0.67 &#177; 0.007, 1924 fibers; Mtmr2-/- saline-treated, 0.68 &#177; 0.003, 2244 fibers; n=4 animals per condition).</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_7-A</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 7-A</infon>
    <infon key="sourcedata_figure_dir">Figure_7-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Western blot analysis of lysates from Pmp22+/- and WT sciatic nerves at P10 shows that Akt phosphorylation (S473) is increased in Pmp22+/- nerves, results are mean &#177; SEM, p=0.0317, two-tailed Mann Whitney U test, representative of two independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_7-B-1</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 7-B-1</infon>
    <infon key="sourcedata_figure_dir">Figure_7-B-1</infon>
    <passage>
      <offset>0</offset>
      <text>B. Western blot analysis of Tace using lysates from Pmp22+/- and WT sciatic nerves at different stages of development. The arrowhead indicates the pro-protein and the arrow shows the cleaved active form of Tace. Representative of two independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_7-B-2</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 7-B-2</infon>
    <infon key="sourcedata_figure_dir">Figure_7-B-2</infon>
    <passage>
      <offset>0</offset>
      <text>B. Tace activity as measured in Pmp22+/- and WT sciatic nerves at P30 (n=6 mice per genotype, results are mean &#177; SEM, p=0.0070, two-tailed Mann Whitney U test).</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_7-C-D-E</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 7-C-D-E</infon>
    <infon key="sourcedata_figure_dir">Figure_7-C-D-E</infon>
    <passage>
      <offset>0</offset>
      <text>C. Representative images of semithin section analysis of sciatic nerves at P45 from Pmp22+/- saline and Pmp22+/- Niaspan-treated mice. Niaspan was administered daily by i.p. injection at 160mg/Kg starting at P15 for 30 days. C'. The percentage of tomacula in sciatic nerves was assessed by ultrastructural analysis, results are mean &#177; SEM, n= 6 animals per condition, p=0.0022, two-tailed Mann Whitney U test, representative of two independent experiments. D. G-ratio analysis on semithin sections of sciatic nerves shows that increased myelin thickness in Pmp22+/- sciatic nerves at P45 is restored to normal values following Niaspan treatment. Mean g-ratio values, WT saline-treated: 0.69 &#177; 0.002, 2052 fibers, n=5 animals; Pmp22+/- saline-treated: 0.66 &#177; 0.003, 2643 fibers, n=6 animals; Pmp22+/- Niaspan-treated, 0.68 &#177; 0.002, 2311 fibers, n=6 animals. WT saline as compared to Pmp22+/- saline-treated, p&lt;0.0001; Pmp22+/- saline-treated as compared to Pmp22+/- Niaspan-treated, p=0.0002; Pmp22+/- Niaspan-treated as compared to WT saline, p=0.0899; repeated measures ANOVA. E. The number of myelinated fibers is similar between the 3 groups analyzed, p=0.4362, nonparametric one-way ANOVA, followed by Dunn's post hoc test.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_8-A</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 8-A</infon>
    <infon key="sourcedata_figure_dir">Figure_8-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Western blot analysis to detect phosphorylation levels of Akt (S473) on lysates from Pmp22-/- and WT mice at P20, with quantification. Results are mean &#177; SEM, p=0.6857, two-tailed Mann Whitney U test, representative of three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_8-B</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 8-B</infon>
    <infon key="sourcedata_figure_dir">Figure_8-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Western blot analysis for Mbp and P0 on lysates from Pmp22-/- and WT mice P20 shows decreased myelin protein expression levels at both time points in Pmp22-/- nerves, results are mean &#177; SEM, p=0.0500 with the exception of the P0 protein level at P20, for which the difference between Pmp22-/- and WT nerves is not statistically significant, p=0.1000, one-tailed Mann Whitney U test, representative of two independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_8-C</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 8-C</infon>
    <infon key="sourcedata_figure_dir">Figure_8-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Representative images of semithin section analysis of WT and Pmp22-/- sciatic nerves at P30. Tomacula are abundant in Pmp22-/- nerves at this age, where both fibers with thicker myelin (in the range of &lt;3-4 &#956;m in diameter) and thinner myelin (with diameters greater than 4 &#956;m, particularly in motor fasicles) can be observed. C'. Niaspan does not ameliorate the phenotype in Pmp22-/- mice, as indicated by the number of tomacula (quantification of the percentage of tomacula in the entire sciatic nerve section, results are mean &#177; SEM, p=0.7400, Mann Whitney U test, n= 15 animals per condition).</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_8-D</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 8-D</infon>
    <infon key="sourcedata_figure_dir">Figure_8-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Growth curve of Pmp22-/- mice treated with Niaspan administered by i.p. injection daily at 160mg/Kg and starting at P15 for 15 days. A significant time by group effect is noted between WT saline and Pmp22-/- saline (group effect p=0.9907 and time effect p=0.0057), indicating that the two groups start with similar weight values but then the WT saline group (n=6 animals) grows more in time. When Pmp22-/- saline (n=5) and Pmp22-/- Niaspan-treated (n=6) are compared, the group effect is statistically significant (p=0.0076) while the time effect is not (p=0.6677), suggesting that these two groups have a similar growth trend but Pmp22-/- Niaspan-treated group starts with a higher baseline weight.</text>
    </passage>
  </document>
  <document>
    <id>5167133 Figure_8-E</id>
    <infon key="sourcedata_document">2439</infon>
    <infon key="doi">10.15252/emmm.201606349</infon>
    <infon key="pmc_id">5167133</infon>
    <infon key="figure">Figure 8-E</infon>
    <infon key="sourcedata_figure_dir">Figure_8-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. Niaspan does not ameliorate myelin thickness as indicated by g-ratio analysis, with axonal diameter distribution: WT 0.68 &#177; 0.003, 2945 fibers, n=5 animals; Pmp22-/- 0.64 &#177; 0.003, 1557 fibers, n= 6 animals; Pmp22-/- Niaspan 0.63 &#177; 0.003, 1445 fibers, n=6 animals, results are mean &#177; SEM. WT saline as compared to Pmp22-/- saline-treated p&lt;0.0001; WT saline as compared to Pmp22-/- Niaspan-treated p&lt;0.0001, repeated measures ANOVA. Note the loss of myelinated fibers in Pmp22-/- nerves for all caliber axons.</text>
    </passage>
  </document>
</collection>
